U nas zapłacisz kartą
Vita C Infusion Mikrodermabrazja - Twoje Klucze do Promiennej Skóry
How Does High-Dose Vitamin C Help Treat Cancer?
High-dose vitamin C has been studied as a treatment for patients with cancer since the 1970s. A Scottish surgeon named Ewan Cameron worked with Nobel Prize-winning chemist Linus Pauling to study the possible benefits of vitamin C therapy in clinical trials of cancer patients in the late 1970s and early 1980's.
Surveys of healthcare practitioners at United States CAM conferences in recent years have shown that high-dose IV vitamin C is frequently given to patients as a treatment for infections, fatigue , and cancers, including breast cancer.
More than fifty years ago, a study suggested that cancer was a disease of changes in connective tissue caused by a lack of vitamin C. In the 1970's, it was proposed that high-dose ascorbic acid could help build resistance to disease or infection and possibly treat cancer.
Intravenous High-Dose Vitamin C in Cancer Therapy
Lewis Cantley received his Ph.D. from Cornell University and did his post-doctoral work at Harvard University. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School in Boston. He is current the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. Jihye Yun received her Ph.D. from Johns Hopkins University, School of Medicine under the mentorship of Bert Vogelstein and did her post-doctoral work with Lewis Cantley at Weill Cornell Medicine. She is currently an Assistant Professor and a CPRIT scholar at Baylor College of Medicine in Houston.
The discovery and isolation of vitamin C was one of the most important advances in improving human nutrition. Scurvy, a severe vitamin C deficiency disease characterized by weakness, lethargy, easy bruising and bleeding, was particularly problematic for sailors on long voyages during the 16th century, where access to fresh fruits and vegetables was limited. In fact, scurvy was the leading cause of naval deaths between the 16th and 18th centuries, killing more sailors than all battles, storms and other diseases combined. It wasn’t until 1747 that Scottish naval physician James Lind demonstrated that consuming oranges and lemons cured and prevented scurvy. However, it took scientists nearly two more centuries to identify the nature of the curative substance contained in citrus fruits, now commonly known as vitamin C. The search for this elusive substance ended in 1932 when Albert Szent-Gyorgyi, a Hungarian biochemist, isolated and identified a 6-carbon carbohydrate, hexuronic acid, as the anti-scurvy factor. Shortly thereafter, Szent-Gyorgyi renamed it “a-scorbic acid”, a reference to its anti-scorbutic properties, and later went on to receive the Nobel Prize in Physiology and Medicine in 1937 for his discoveries.
Concluding Remarks
Vitamin C as a cancer therapy has had a controversial past. What has been intriguing are small clinical trials that suggest some responses, but with no clear rationale for why cancers should respond to vitamin C or a path forward for explaining which patients are most likely to respond. Now a growing number of preclinical studies are showing how high-dose vitamin C might benefit cancer patients. Importantly, these preclinical studies provide a clear rationale and potential biomarkers that may help personalize the therapeutic approach and identify patient populations that are likely to respond to high-dose vitamin C therapy. Since the mechanisms of action of vitamin C are becoming better defined, we can propose vitamin C combinations in a more rational, hypothesis-driven manner. In addition, given the current high financial cost of new cancer drugs, it seems rational to improve the effectiveness of current therapies by studying their clinical interactions with vitamin C. In our view, the implementation of this treatment paradigm could provide benefit to many cancer patients.
This work was supported by the US National Institutes of Health (NIH) grant (R35 CA197588), Stand Up to Cancer–American Association for Cancer Research grant (SU2C-AACR-DT22-17), and the Damon Runyon Cancer Research Foundation. Lewis Cantley is a founder and member of the senior advisory boards of Agios Pharmaceuticals and Petra Pharmaceuticals, which are developing novel therapies for cancer. The Cantley laboratory also receives financial support from Petra Pharmaceuticals.
Taking RAS Research to Space
What Drugs Interact with High-Dose Vitamin C?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs. High-dose vitamin C, when combined with some anticancer drugs, may cause them to be less effective. So far, these effects have been seen only in some laboratory and animal studies. No clinical trials have been done to further research these drug interactions in humans.
Laboratory studies and animal studies have been done to find out if high-dose vitamin C may be useful in preventing or treating cancer.
Laboratory studies
Many laboratory studies have been done to find out how high-dose vitamin C may cause the death of cancer cells. The anticancer effect of vitamin C in different types of cancer cells involves a chemical reaction that makes hydrogen peroxide, which may kill cancer cells.
Laboratory studies have shown the following:
- Treatment with high-dose vitamin C slowed the growth and spread of prostate, pancreatic, liver, colon, malignant mesothelioma, neuroblastoma, and other types of cancer cells.
- Combining high-dose vitamin C with certain types of chemotherapy may be more effective than chemotherapy alone:
- Ascorbic acid with arsenic trioxide may be more effective in ovarian cancer cells.
- Ascorbic acid with gemcitabine may be more effective in pancreatic cancer cells.
- Ascorbic acid with gemcitabine and epigallocatechin-3-gallate (EGCG) may be more effective in malignant mesothelioma cells.
However, not all laboratory studies combining vitamin C with anticancer therapies have shown benefit. Combining dehydroascorbic acid, a particular form of vitamin C, with chemotherapy made it less effective in killing some kinds of cancer cells.
Animal studies
Studies of high-dose vitamin C have been done in animal models (animals given a disease either the same as or like a disease in humans).
Ingredients overview
Key Ingredients
Show all ingredients by function
Other Ingredients
Ingredient name what-it-does irr. , com. ID-Rating Aqua solvent Alumina viscosity controlling, abrasive/scrub Caprylic/Capric Triglyceride emollient Vitis Vinifera Seed Oil antioxidant, emollient goodie Glycerin skin-identical ingredient, moisturizer/humectant 0 , 0 superstar Sodium Polyacrylate viscosity controlling Urea skin-identical ingredient, moisturizer/humectant goodie Myrciaria Dubia Fruit Extract Hippophae Rhamnoides Oil antioxidant, emollient goodie Helianthus Annuus Seed Oil emollient 0 , 0 goodie Rosmarinus Officinalis Leaf Extract antioxidant, soothing, antimicrobial/antibacterial goodie Glycine Soja Oil emollient, perfuming 0 , 3 goodie Sodium Hyaluronate skin-identical ingredient, moisturizer/humectant 0 , 0 goodie Panthenol soothing, moisturizer/humectant 0 , 0 goodie Propanediol solvent, moisturizer/humectant Ascorbyl Palmitate antioxidant 0 , 2 icky Tocopherol antioxidant 0 - 3 , 0 - 3 goodie Hydrogenated Vegetable Glycerides Citrate emollient, emulsifying Propylene Glycol moisturizer/humectant, solvent 0 , 0 Lecithin emollient, emulsifying goodie Caprylyl Glycol moisturizer/humectant, emollient Beta-Sitosterol Squalene skin-identical ingredient, antioxidant, emollient goodie Phenoxyethanol preservative Lactic Acid exfoliant, moisturizer/humectant, buffering superstar Disodium EDTA chelating Citrus Limon Peel Oil perfuming icky Parfum perfuming icky Limonene perfuming, solvent icky Linalool perfuming icky Hexyl Cinnamal perfuming icky Citral perfuming icky Geraniol perfuming icky